The most clearly defined groups who may be considered in future include individuals with: Metabolic dysfunction-associated steatotic liver disease (MASLD) particularly those with concurrent obesity, type 2 diabetes, or metabolic syndrome Metabolic dysfunction-associated steatohepatitis (MASH) the progressive inflammatory subtype associated with fibrosis and risk of cirrhosis Obesity with elevated liver enzymes (ALT/AST) where hepatic steatosis has been confirmed on imaging Type 2 diabetes with evidence of hepatic fat accumulation , where current glucose-lowering therapies have not adequately addressed liver disease Patients with significant hepatic fibrosis (stage F2 or above) represent a group with particularly high unmet need, as there are currently no licensed pharmacological treatments specifically approved for MASH in the UK
If patients receive GLP1 medications outside their primary health system (for example, from telehealth) or change providers during the treatment, the EHR data collected in our study may not capture the full course of treatment, and this may explain our observation of generally shorter treatment durations, and hence less weight loss, recorded in EHRs
Time of day Does it matter when you inject
The Rationale Behind Peptide Stacking Some people consider a Retatrutide stack because they hope to support fat loss while maintaining lean body mass during weight reduction
Injecting slowly, over 20 to 30 seconds rather than in a single rapid push, allows the surrounding subcutaneous tissue more time to equilibrate as the solution is introduced
